Sclerosing bone dysplasias: Leads toward novel osteoporosis treatments

Current Osteoporosis Reports

Volumn 12, Issue 3, 2014, Pages 243-251

  Fijalkowski, Igor ^a   Boudin, Eveline ^a   Mortier, Geert ^a   Van Hul, Wim ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Camurati Engelmann disease; Craniodiaphyseal dysplasia; Craniometaphyseal dysplasia; Expansile skeletal hyperphosphatasia; Familial expansile osteolysis; High bone mass phenotype; Ostaoectasia with hyperphosphatasia,; Osteopetrosis; Osteopoikilosis; Osteoporosis; Paget's disease of bone; Pycnodysostosis; Raine syndrome; Sclerosing bone dysplasia; Sclerosteosis; Treatment; Van Buchem disease

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; BAFILOMYCIN A1; BHQ 880; BISPHOSPHONIC ACID DERIVATIVE; BLOSOZUMAB; BPS 804; CATHEPSIN K INHIBITOR; CHLORIDE CHANNEL; CHLORIDE CHANNEL BLOCKING AGENT; CONCANAMYCIN A; DENOSUMAB; DICKKOPF 1 PROTEIN; FR 167356; FR 202126; MIV 711; MONOCLONAL ANTIBODY; NS 3736; ODANACATIB; ONO 5334; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ROMOSOZUMAB; SB 242784; SCLEROSTIN; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT;

ALBERS SCHOENBERG DISEASE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BONE DENSITY; BONE DYSPLASIA; BONE MASS; BONE TURNOVER; CAMURATI ENGELMANN DISEASE; CRANIODIAPHYSEAL DYSPLASIA; CRANIOMETAPHYSEAL DYSPLASIA; EXPANSILE SKELETAL HYPERPHOSPHATASIA; FAMILIAL EXPANSILE OSTEOLYSIS; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; HYPEROSTOSIS; HYPOHIDROTIC ECTODERMAL DYSPLASIA; LOSS OF FUNCTION MUTATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOECTASIA WITH HYPERPHOSPHATASIA; OSTEOPATHIA STRIATA; OSTEOPOROSIS; OSTEOSCLEROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PYCNODYSOSTOSIS; RAINE SYNDROME; REVIEW; SCLEROSING BONE DYSPLASIA; UNSPECIFIED SIDE EFFECT; VAN BUCHEM DISEASE; WNT SIGNALING PATHWAY; X CHROMOSOMAL INHERITANCE; BONE DEVELOPMENT; CHONDRODYSPLASIA; DRUG DEVELOPMENT; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; OSTEOLYSIS;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOCHONDRODYSPLASIAS; OSTEOGENESIS; OSTEOPOROSIS; OSTEOSCLEROSIS;

EID: 84906316938     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-014-0220-5     Document Type: Review

References (70)

1. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377(9773):1276-87.
2. Ferrari S. Human genetics of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008;22(5):723-35.
3. Kornak U et al. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet. 2000;9(13):2059-63. (Pubitemid 30642671)
4. • Sobacchi C et al. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9(9):522-36. Comprehensive and up-to-date review on the heterogeneous group of Osteopetroses.
5. Kornak U et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001;104(2):205-15. (Pubitemid 32174837)
6. Chalhoub N et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med. 2003;9:399-406. (Pubitemid 36460073)
7. Sly WS et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med. 1985;313:139-45. (Pubitemid 15047455)
8. Guerrini MM et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet. 2008;83(1):64-76. (Pubitemid 351916706)
9. Sobacchi C et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007;39(8):960-2. (Pubitemid 47185178)
10. Smahi A et al. The NF-kappaB signaling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet. 2002;11(20):2371-5. (Pubitemid 35174700)
11. Van Wesenbeeck L et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest. 2007;117(4):919-30. (Pubitemid 46556748)
12. Aker M et al. An SNX10 mutation causes malignant osteopetrosis of infancy. J Med Genet. 2012;49(4):221-6.
13. Cleiren E et al. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet. 2001;10(25):2861-7. (Pubitemid 34030917)
14. Bollerslev J et al. Autosomal dominant osteopetrosis revisited: lessons from recent studies. Eur J Endocrinol. 2013;169(2):R39-57.
15. Gelb BD et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236-8.
16. Little RD et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70(1):11-9. (Pubitemid 34031693)
17. Boyden LM et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513-21. (Pubitemid 34755690)
18. Ai M et al. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet. 2005;77(5):741-53. (Pubitemid 41513277)
19. Balemans W et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537-43. (Pubitemid 32184286)
20. Brunkow ME et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577-89. (Pubitemid 32202753)
21. Leupin O et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286(22):19489-500.
22. Balemans W et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91-7. (Pubitemid 34146376)
23. Kim SJ et al. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum Genet. 2011;129(5):497-502.
24. Jenkins ZA et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 2009;41(1):95-100.
25. Nurnberg P et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, results in craniometaphyseal dysplasia. Nat Genet. 2001;28(1):37-41. (Pubitemid 32405813)
26. Reichenberger E et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001;68(6):1321-6. (Pubitemid 32510607)
27. Hu Y et al. A novel autosomal recessive GJA1 missense mutation linked to Craniometaphyseal dysplasia. PLoS One. 2013;8(8):e73576.
28. Janssens K et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet. 2000;26(3):273-5.
29. Kinoshita A et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet. 2000;26(1):19-20.
30. Hellemans J et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet. 2004;36(11):1213-8. (Pubitemid 41288972)
31. Mumm S et al. Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis. J Bone Miner Res. 2007;22(2):243-50. (Pubitemid 46167795)
32. Ababneh FK et al. Hereditary deletion of the entire FAM20C gene in a patient with Raine syndrome. Am J Med Genet A. 2013;161A(12):3155-60.
33. Wang X et al. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets inmice. PLoS Genet. 2012;8(5):e1002708.
34. Singer FR, Mills BG. Evidence for a viral etiology of Paget's disease of bone. Clin Orthop Relat Res. 1983;178:245-51. (Pubitemid 13001167)
35. Laurin N et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70(6):1582-8. (Pubitemid 34533906)
36. Hocking LJ et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet. 2002;11(22):2735-9. (Pubitemid 35214900)
37. Johnson JO et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68(5):857-64.
38. Whyte MP et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002;347(3):175-84. (Pubitemid 34764821)
39. Hughes AE et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24(1):45-8. (Pubitemid 30041418)
40. Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res. 2002;17(1):26-9. (Pubitemid 33150993)
41. Whyte MP et al. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. J Bone Miner Res. 2000;15(12):2330-44.
42. Boudin E et al. No mutations in the serotonin related TPH1 and HTR1B genes in patients with monogenic sclerosing bone disorders. Bone. 2013;55(1):52-6.
43. Boudin E et al. Mutations in sFRP1 or sFRP4 are not a common cause of craniotubular hyperostosis. Bone. 2013;52(1):292-5.
44. Pangrazio A et al. Exome sequencing identifies CTSK mutations in patients originally diagnosed as intermediate osteopetrosis. Bone. 2014;59:122-6.
45. •• Lazarus S, Zankl A, Duncan EL. Next-generation sequencing: a frameshift in skeletal dysplasia gene discovery. Osteoporos Int. 2014;25(2):407-22. Reviews the insights into Sclerosing Bone Dysplasias provided by novel sequencing techniques.
46. Borra VM et al. Localization of the gene for hyperostosis cranialis interna to chromosome 8p21 with analysis of three candidate genes. Calcif Tissue Int. 2013;93(1):93-100.
47. Borra VM et al. Localization of the gene for X-linked calvarial hyperostosis to chromosome Xq27.3-Xqter. Bone. 2014;58:67-71.
48. Pagon RA, Beckwith JB, Ward BH. Calvarial hyperostosis: a benign X-linked recessive disorder. Clin Genet. 1986;29(1):73-8. (Pubitemid 16174750)
49. Zhang Y et al. Novel and recurrent germline LEMD3 mutations causing Buschke-Ollendorff syndrome and osteopoikilosis but not isolated melorheostosis. Clin Genet. 2009;75(6):556-61.
50. Kasapkara CS et al. An extremely rare case: osteosclerotic metaphyseal dysplasia. Genet Couns. 2013;24(1):69-74.
51. Yao AL, Camacho PM. Osteomesopyknosis: a case report and review of sclerosing bone disorders. Endocr Pract. 2014:1-14. doi:10.4158/EP13352.CR.
52. Das S, Crockett JC. Osteoporosis - a current view of pharmacologic prevention and treatment. Drug Des Devel Ther. 2013;7:435-48.
53. Leder BZ, et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99(5):1694-700.
54. Schaller S et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res. 2004;19(7):1144-53. (Pubitemid 41110567)
55. Qin A et al. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption. Int J Biochem Cell Biol. 2012;44(9):1422-35.
56. Saftig P et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95(23):13453-8. (Pubitemid 28522993)
57. Duong LT. Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Reports, 20. doi:10.1038/bonekey.2012. 67.
58. Langdahl B et al. Odanacatib in the treatment of postmenopausal womenwith low bonemineral density: 5 years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251-8.
59. Sims NA, Ng KW. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. Curr Osteoporos Rep. 2014;12(1):98-106.
60. Chen M et al. Emerging therapeutic targets for osteoporosis treatment. Expert Opin Ther Target. 2014;18(7):817-831.
61. Ng KW, Martin TJ. New therapeutics for osteoporosis. Curr Opin Pharmacol. 2014;16C:58-63.
62. Boudin E et al. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases. Semin Arthritis Rheum. 2013;43(2):220-40.
63. •• McClung MR et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412-20. The most recent report on the clinical trials of the most promising osteoporosis treatment in development.
64. Kedlaya R et al. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Sci Transl Med. 2013;5(211):211ra158.
65. • Sinder BP et al. Sclerostin antibody improves skeletal parameters in a Brtl/+mousemodel of osteogenesis imperfecta. J Bone Miner Res. 2013;28(1):73-80. Supports the therapeutic effect of sclerostin antibody in murine model of Osteogenesis Imperfecta. Demonstrates the diversity of this therapeutic agent.
66. • Chang MK et al. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res. 2014;29(1):29-42. Comprehensive studies providing insights into the biology of sclerostin inhibition.
67. van Lierop AH et al. Serum Dickkopf 1 levels in sclerostin deficiency. J Clin Endocrinol Metab. 2014;99(2):E252-6.
68. Morvan F et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21(6):934-45. (Pubitemid 43788000)
69. Moore WJ et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II. Bioorg Med Chem. 2010;18(1):190-201.
70. Moore WJ et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J Med Chem. 2009;52(1):105-16.